Acetyl Hexapeptide-8 — sold under the trade name Snap-8 and also referenced as Argireline (an earlier brand for the same molecule) — is a synthetic hexapeptide developed for topical cosmetic research. It is one of a small number of peptide compounds in research-vendor catalogues with a defined cosmetic-formulation history and an established INCI designation. This monograph lays out its chemical identity, SNAP-25 / SNARE-complex mechanism, the published research record, and the relationship between its multiple brand names.
Chemical identity and structure.
Acetyl Hexapeptide-8 has the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂. It is a linear N-acetylated, C-amidated hexapeptide with molecular formula C₃₄H₆₀N₁₄O₁₂S and molecular weight 888.05 g/mol. The trade names Snap-8 and Argireline both refer to this molecule; Acetyl Hexapeptide-3 is an earlier numbering for the same compound, and Acetyl Hexapeptide-8 is the current INCI designation. The compound is supplied as a lyophilized white-to-off-white powder, water-soluble, and most commonly formulated in topical cosmetic preparations.
Mechanism of action.
Acetyl Hexapeptide-8 is a research analog of the N-terminal region of SNAP-25, a key component of the SNARE complex that mediates synaptic-vesicle exocytosis at the neuromuscular junction. The peptide is hypothesised to competitively inhibit SNARE-complex assembly, reducing acetylcholine release and consequently reducing muscle contraction at the formulation site — a mechanism conceptually parallel to botulinum toxin, but acting upstream and with far weaker affinity. The published characterisation of this mechanism is primarily in-vitro on SNARE-complex assays and in topical-formulation models, not in clinical neurophysiology.
Research applications and the evidence base.
Published research is dominated by cosmetic-formulation studies of expression-line softening in topical preparations, with a small number of split-face randomised pilots reporting measurable reductions in wrinkle depth. Penetration is a known limitation — the molecule's size and charge profile constrain dermal absorption, and most published efficacy data depends on formulation vehicles (liposomal, encapsulated) that improve delivery. There is no completed pivotal human clinical trial of the compound as a stand-alone therapy outside the cosmetic-formulation literature.
Research context.
Researchers studying topical neuropeptide cosmetics typically work with Acetyl Hexapeptide-8 as the canonical SNAP-25-mimetic comparator. The compound is sometimes paired with copper tripeptides (GHK-Cu, AHK-Cu) in dermal-formulation research, and sometimes with growth-factor mimetics (Matrixyl / palmitoyl pentapeptide) in combined wrinkle-research formulations.
Human clinical trial data.
In the randomized, placebo-controlled study by Wang and colleagues (2013), 60 Chinese subjects received argireline or placebo in a 3:1 ratio, applied to their peri-orbital wrinkles twice daily for 4 weeks (PubMed).
Storage and handling.
Lyophilized Acetyl Hexapeptide-8 should be kept refrigerated (2–8 °C) and protected from light. The peptide does not tolerate repeated freeze-thaw of solutions and should not be heated above ~40 °C during formulation.
Quality and COA considerations.
A meaningful COA should confirm identity via mass spectrometry (888.05 g/mol target), purity by HPLC (≥95% is the practical cosmetic-grade benchmark; ≥98% for research-grade vials), and explicit name disambiguation given the multiple synonyms (Snap-8, Argireline, Acetyl Hexapeptide-3, Acetyl Hexapeptide-8 all describe the same molecule).
Research-use note: This monograph is an educational summary of the published research literature for Acetyl Hexapeptide-8 (Snap-8 / Argireline). The compound is widely formulated in cosmetic preparations but is not approved for any pharmaceutical indication in any jurisdiction known to VialTalk. Nothing here is medical advice or a usage recommendation.
